Objective This study evaluated the efficacy and safety of various antipsychotic drugs in the treatment of tic disorders by Meta analysis. Methods RCTs evaluating antipsychotic drugs for TDs were identified from PubMed， Embase， Cochrane library， four Chinese database， relevant reference lists and the references of systematic reviews. We used Stata to perform meta-analysis. Results After removing duplicates， screening titles and abstracts， and reading full texts， 60 RCTs met the inclusion criteria， Total of 4 077 patients were included. The age of participants ranged from 2 to 65 years. The publication year was between 1978 and 2015. The sample size ranged from 4 to 180（ median 61）. There was no statistical significant difference in improving tic severity between the groups of risperidone vs haloperidol（ P=0.54）， aripiprazole vs haloperidol（ P=0.45）， tiapride hydrochloride vs haloperidol（ P=0.52）， piperidin vs haloperidol（ P=0.67）， olanzapine vs haloperidol（ P=0.15）， piperidin vs placebo（ P=0.06）. Quetiapine was better than haloperidol， aripiprazole was better than tiapride hydrochloride， risperidone and haloperidol were superior to placebo in improving the tic symptom score， and the differences were statistically significant（ P＜0.05）. Totally 42 RCTs reported adverse reactions. Atypical antipsychotic drugs were well tolerated without serious adverse effects. Conclusions Typical antipsychotics were efficacious in the reduction of tic severity， however the adverse effects（ AE） restricted its clinical application. Atypical antipsychotics（ risperidone， aripiprazole， olanzapine， ziprasidone， quetiapine） significantly improve tic symptoms with fewer AEs. The efficacy of risperidone and aripiprazole were supported by strong evidence and quetiapine is a promising therapy for TDs. Ziprasidone and olanzapine are also effective， but the evidence is lacking. The current evidence of antipsychotics in the treatment of TDs is lacking and the quality is not high， long-term efficacy and safety need to be confirmed in further.